Company Projected Revenue: Solid Bio (SLDB)
The target sales volume indicator reflects market growth expectations, where the value 0.00 serves as the target level. Solid Biosciences Inc. (SLDB) is attracting leading geneticists, securing staff through stock options. Financial stability is based on grants and partnerships amid negative FCF. The primary threat remains potential therapy side effects, which could wipe out the company's capitalization.
Summary analytical data breakdowns for Solid Corp (SLDB)
- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
- balance sheet equity data:
- debt and liquidity details:
Total Debt to Capital Solid Biosciences Inc.|SLDB - Long-Term Liabilities to Capital|Short-Term Debt to Equity Solid Biosciences|SLDB - Company Aggregate Debt|Debts to Book Capitalization Solid Biosciences|SLDB - Company Long-Term Liabilities|Company Short-Term Debts Solid Biosciences|Quick Liquidity solidbio.com
- earnings and market ratios statistics:
SLDB - Net Financial Result|Future Profit Solid Biosciences Inc.|SLDB - Company Value to Net Income|Forward P/E Multiple Solid Corp|SLDB - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Solid Biosciences Inc.|SLDB - Operating profit before amortization|Net earnings per share (EPS TTM) Solid Biosciences|SLDB - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months solidbio.com|SLDB - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Solid Biosciences Inc.
- total revenue and sales volume data:
Summary company analytics:Solid Biosciences Inc
This indicator measures market expectations for future revenue, reflecting the analysts' consensus forecast regarding the business's ability to generate cash flow over the long term. For Solid Biosciences Inc. (SLDB), the trend of prospective sales is critically dependent on the reliability of external CMO contractors, as the lack of in-house capacity makes any gene therapy implementation forecasts sensitive to the operational risks of outsourcing.
Competitors of Solid Biosciences Inc.
Company Future Sales Volume TEM (Tempus AI)|Company Future Sales Qiagen Group|Company Projected Revenue Ionis Pharma IONS|RGEN - Company Future Sales Volume|RNA - Company Projected Revenue|Company Future Revenue CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Company Projected Revenue|Company Expected Revenue RARE (Ultragenyx)|Company Future Sales Volume BEAM|Projected Sales Volume Sarepta Corp|Company Projected Revenue Twist Bioscience, Inc. (TWST)|Company Future Sales Volume 10x Genomics TXG|Company Projected Revenue Intellia Therapeutics NTLA|Company Projected Revenue Volume STOK (Stoke Therapeutics, Inc.)|BLFS - Company Projected Revenue|Company Expected Sales Volume Wave Pharma|mazetx.com (MAZE) - Company Projected Revenue|SION - Company Future Sales|PRME (Prime Medicine Inc) - Projected Sales Volume|Taysha Gene Therapies, Inc. - Company Expected Revenue|Projected Sales Volume QURE|MGTX: Company Expected Revenue|Company Projected Revenue REGENXBIO RGNX|OCGN - Company Future Sales Volume|pacb.com - Projected Sales Volume|Benitec (BNTC) - Company Future Sales Volume|DSGN: Projected Sales Volume|RCKT - Company Future Sales|FDMT: Company Future Sales|Company Revenue Forecast LXEO (lexeotx.com)|Company Projected Revenue Korro Bio Inc. (KRRO)|Company Projected Revenue Volume EDIT|Projected Sales Volume SLN (Silence Therapeutics PLC)|Company Future Revenue PRQR|CDXS - Company Projected Revenue|SGMO (Sangamo Therapeutics) - Company Revenue Forecast|NAUT: Projected Sales Volume|Company Revenue Forecast MGX|DTIL (precisionbiosciences.com) - Projected Sales Volume|Company Revenue Forecast GBIO (Generation Bio Co.)|Company Projected Revenue Boundless Bio (BOLD)|Exicure - Company Revenue Forecast|Projected Sales Volume IMNN (imunon.com)|Company Future Sales Phio Pharmaceuticals (PHIO)|MBIO: Company Future Sales Volume|Company Future Revenue RNAZ (transcodetherapeutics.com)|Bionano Genomics, Inc. (BNGO) - Company Projected Revenue|APDN - Company Future Sales|Company Future Sales Volume BLUE|Projected Sales Volume immunoprecise.com|Projected Sales Volume OMGA|Company Future Sales Singular Genomics Corp|Regulus Therapeutics - Company Future Sales Volume|SYRS (Syros Pharmaceuticals) - Company Expected Revenue|Telesis Bio Inc. - Projected Sales Volume|Company Future Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX: Projected Sales Volume
